The vaccine manufacturer Moderna and IBM, a technology company, will work together on implementation of technologies such as artificial intelligence, blockchain and hybrid cloud, to improve COVID-19 vaccine management in the U.S.
You might also like: An interview with European and U.S. experts about the need for global monitoring of vaccine use as well as its safety and effectiveness. Learn more
The collaboration will first be testing open, standardised, technology-enabled approaches to vaccine distribution that would allow for more efficient supply management and a near real-time monitoring of vaccine administration. With this, the companies are looking into the possibilities of secure and seamless data sharing between various stakeholders, from authorities to providers to individuals.
Initially the focus will be on:
- Solutions for tracing individual batches of vaccine at all stages, from manufacturing to administration, and avoiding potential disruptions in the supply chain.
- IBM’s blockchain-based Digital Health Pass for health credentials verification for work, travel, shopping and other types of activities. The solution incorporates data on COVID-19 test results, vaccination records, temperature checks, etc.
Moderna’s two-dose mRNA vaccine has been approved for emergency use in the U.S. and in Europe.
Image credit: carmengabriela